{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:18:31Z","timestamp":1740719911813,"version":"3.38.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research and Cultivation Fund of Hainan Medical University","award":["HYPY2020015"],"award-info":[{"award-number":["HYPY2020015"]}]},{"name":"Hainan Province Clinical Medical Center","award":["QWYH202175"],"award-info":[{"award-number":["QWYH202175"]}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hainan Province","doi-asserted-by":"publisher","award":["820RC771"],"award-info":[{"award-number":["820RC771"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key R&D Projects of Hainan Province","award":["ZDYF2022SHFZ074"],"award-info":[{"award-number":["ZDYF2022SHFZ074"]}]},{"name":"Specific Research Fund of The Innovation Platform for Academicians of Hainan Province","award":["YSPTZX202311"],"award-info":[{"award-number":["YSPTZX202311"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02406-9","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:48:49Z","timestamp":1740642529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study"],"prefix":"10.1186","volume":"30","author":[{"given":"Bangbei","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"9","key":"2406_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.31128\/AJGP-11-19-5142","volume":"49","author":"A Hutchinson","year":"2020","unstructured":"Hutchinson A, Nesbitt A, Joshi A, Clubb A, Perera M. Overactive bladder syndrome: management and treatment options. Aust J Gen Pract. 2020;49(9):593\u20138.","journal-title":"Aust J Gen Pract"},{"issue":"8","key":"2406_CR2","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3390\/biomedicines10081957","volume":"10","author":"LN Hsu","year":"2022","unstructured":"Hsu LN, Hu JC, Chen PY, Lee WC, Chuang YC. Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies. Biomedicines. 2022;10(8):1957.","journal-title":"Biomedicines"},{"issue":"4","key":"2406_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/luts.12262","volume":"11","author":"LC Chen","year":"2019","unstructured":"Chen LC, Kuo HC. Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms. 2019;11(4):177\u201381.","journal-title":"Low Urin Tract Symptoms"},{"key":"2406_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TCRM.S269318","volume":"19","author":"C Shaw","year":"2023","unstructured":"Shaw C, Gibson W. Assessing quality-of-life of patients taking mirabegron for overactive bladder. Ther Clin Risk Manag. 2023;19:27\u201333.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2406_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000447205","volume":"11","author":"E Leron","year":"2018","unstructured":"Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11(3):117\u201325.","journal-title":"Curr Urol"},{"key":"2406_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","volume":"87","author":"HB Goldman","year":"2016","unstructured":"Goldman HB, Anger JT, Esinduy CB, Zou KH, Russell D, Luo X, Ntanios F, Carlsson MO, Clemens JQ. Real-world patterns of care for the overactive bladder syndrome in the United States. Urology. 2016;87:64\u20139.","journal-title":"Urology"},{"issue":"2","key":"2406_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mayocp.2019.11.024","volume":"95","author":"R Raju","year":"2020","unstructured":"Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2406_CR8","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","volume":"38","author":"MJ Kennelly","year":"2021","unstructured":"Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison. Adv Ther. 2021;38(11):5452\u201364.","journal-title":"Adv Ther"},{"key":"2406_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2022-4-2","volume":"11","author":"M Kennelly","year":"2022","unstructured":"Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022;11:1.","journal-title":"Drugs Context"},{"issue":"2","key":"2406_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/luts.12417","volume":"14","author":"K Tachikawa","year":"2022","unstructured":"Tachikawa K, Kyoda Y, Fukuta F, Kobayashi K, Masumori N. Efficacy of vibegron in patients with overactive bladder: multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19\u201301. Low Urin Tract Symptoms. 2022;14(2):109\u201316.","journal-title":"Low Urin Tract Symptoms"},{"issue":"7","key":"2406_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/fca-2023-0044","volume":"19","author":"MA Weber","year":"2023","unstructured":"Weber MA, Lucioni A, Gregg SG, Owens-Grillo J. A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder. Future Cardiol. 2023;19(7):363\u201370.","journal-title":"Future Cardiol"},{"issue":"5","key":"2406_CR12","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR). J Urol. 2021;205(5):1421\u20139.","journal-title":"J Urol"},{"issue":"3","key":"2406_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/luts.12475","volume":"15","author":"W He","year":"2023","unstructured":"He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis. Low Urin Tract Symptoms. 2023;15(3):80\u20138.","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"2406_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/nau.24387","volume":"39","author":"H Shi","year":"2020","unstructured":"Shi H, Chen H, Zhang Y, Cui Y. The efficacy and safety of Vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials. Neurourol Urodyn. 2020;39(5):1255\u201363.","journal-title":"Neurourol Urodyn"},{"key":"2406_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/TCRM.S310371","volume":"18","author":"J Frankel","year":"2022","unstructured":"Frankel J, Staskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C. An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder. Ther Clin Risk Manag. 2022;18:171\u201382.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"2406_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"issue":"3","key":"2406_CR17","doi-asserted-by":"publisher","DOI":"10.2196\/19266","volume":"6","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Hultgren KE. Complementing the US food and drug administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis. JMIR Public Health Surveill. 2020;6(3): e19266.","journal-title":"JMIR Public Health Surveill"},{"issue":"11","key":"2406_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19(11):1505\u201311.","journal-title":"Expert Opin Drug Saf"},{"key":"2406_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13: 851246.","journal-title":"Front Pharmacol"},{"key":"2406_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","volume":"14","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q. A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. 2022;14:789\u2013802.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2406_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11884-023-00689-4","volume":"18","author":"D Jericevic","year":"2023","unstructured":"Jericevic D, Brucker B. Telemedicine in overactive bladder syndrome. Curr Bladder Dysfunct Rep. 2023;18(2):103\u20138.","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"7","key":"2406_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/nau.20235","volume":"25","author":"MM Donaldson","year":"2006","unstructured":"Donaldson MM, Thompson JR, Matthews RJ, Dallosso HM, McGrother CW. Leicestershire MRCISG: the natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn. 2006;25(7):709\u201316.","journal-title":"Neurourol Urodyn"},{"key":"2406_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/IJWH.S369588","volume":"15","author":"D Robinson","year":"2023","unstructured":"Robinson D, O\u2019Kane M, Cardozo L. Adherence to overactive bladder syndrome treatments recent developments and future perspectives. Int J Womens Health. 2023;15:799\u2013811.","journal-title":"Int J Womens Health"},{"issue":"1","key":"2406_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12894-023-01240-7","volume":"23","author":"RR Dmochowski","year":"2023","unstructured":"Dmochowski RR, Rovner ES, Kennelly MJ, Newman DK, Abedinzadeh L, Snyder D, Thomas E, Haag-Molkenteller C, Rosenberg MT. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder. BMC Urol. 2023;23(1):64.","journal-title":"BMC Urol"},{"issue":"1","key":"2406_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/13696998.2022.2115754","volume":"25","author":"JV Chen","year":"2022","unstructured":"Chen JV, Klein TM, Nesheim J, Mudd PN Jr. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States. J Med Econ. 2022;25(1):1092\u2013100.","journal-title":"J Med Econ"},{"issue":"5","key":"2406_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bju.15020","volume":"125","author":"M Yoshida","year":"2020","unstructured":"Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Efficacy of vibegron, a novel beta3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125(5):709\u201317.","journal-title":"BJU Int"},{"issue":"2","key":"2406_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7326\/0003-4819-106-2-331_1","volume":"106","author":"RM Cass","year":"1987","unstructured":"Cass RM. Adult respiratory distress syndrome and trimethoprim-sulfamethoxazole. Ann Intern Med. 1987;106(2):331.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2406_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14448","volume":"34","author":"BE Lacy","year":"2022","unstructured":"Lacy BE, King J, Shortino D, Schaumburg C, Haag-Molkenteller C, Chey WD. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. Neurogastroenterol Motil. 2022;34(12): e14448.","journal-title":"Neurogastroenterol Motil"},{"issue":"4","key":"2406_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.juro.2013.02.104","volume":"190","author":"KE Andersson","year":"2013","unstructured":"Andersson KE, Martin N, Nitti V. Selective beta(3)-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173\u201380.","journal-title":"J Urol"},{"issue":"5","key":"2406_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1517\/14740338.2016.1160055","volume":"15","author":"MC Michel","year":"2016","unstructured":"Michel MC, Gravas S. Safety and tolerability of beta3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Expert Opin Drug Saf. 2016;15(5):647\u201357.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2406_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"2","key":"2406_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial. J Urol. 2024;212(2):256\u201366.","journal-title":"J Urol"},{"issue":"6","key":"2406_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/biom13061005","volume":"13","author":"ILO Buxton","year":"2023","unstructured":"Buxton ILO, Asif H, Barnett SD. beta3 receptor signaling in pregnant human myometrium suggests a role for beta3 agonists as tocolytics. Biomolecules. 2023;13(6):1005.","journal-title":"Biomolecules"},{"issue":"17","key":"2406_CR34","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.3390\/ijms241713132","volume":"24","author":"Y Wang","year":"2023","unstructured":"Wang Y, Anesi J, Maier MC, Myers MA, Oqueli E, Sobey CG, Drummond GR, Denton KM. Sympathetic nervous system and atherosclerosis. Int J Mol Sci. 2023;24(17):13132.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2406_CR35","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","volume":"8","author":"H Mostafaei","year":"2022","unstructured":"Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, et al. Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8(4):1072\u201389.","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2406_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40266-020-00829-z","volume":"38","author":"S Varano","year":"2021","unstructured":"Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged >\/=65 and >\/=75 years: subpopulation analysis from the EMPOWUR randomized, international. Phase III Study Drugs Aging. 2021;38(2):137\u201346.","journal-title":"Phase III Study Drugs Aging"},{"issue":"5","key":"2406_CR37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective beta(3)-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73(5):783\u201390.","journal-title":"Eur Urol"},{"issue":"4","key":"2406_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/luts.12480","volume":"15","author":"H Sato","year":"2023","unstructured":"Sato H, Otsuka S, Tsukada S. Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial. Low Urin Tract Symptoms. 2023;15(4):129\u201338.","journal-title":"Low Urin Tract Symptoms"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02406-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02406-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02406-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:49:01Z","timestamp":1740642541000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02406-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2406"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02406-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}